Hatzioannou Aikaterini, Nayar Saba, Gaitanis Anastasios, Barone Francesca, Anagnostopoulos Constantinos, Verginis Panayotis
Clinical, Experimental Surgery & Translational Research, Biomedical Research Foundation Academy of Athens , Athens, Greece.
College of Medical and Dental Sciences, University of Birmingham , Birmingham, UK.
Oncoimmunology. 2016 Jul 29;5(9):e1216289. doi: 10.1080/2162402X.2016.1216289. eCollection 2016.
The beneficial effects of checkpoint blockade in tumor immunotherapy are limited to patients with increased tumor-infiltrating lymphocytes (TILs). Delineation of the regulatory networks that orchestrate the presence of TILs holds great promise for the design of effective immunotherapies. Podoplanin/gp38 (PDPN)-expressing lymph node stromal cells (LNSCs) are present in tumor stroma; however, their effect in the regulation of TILs remains elusive. Herein we demonstrate that intratumor injection of ex-vivo-isolated PDPN LNSCs into melanoma-bearing mice induces elimination of TILs and promotes tumor growth. In support, PDPN LNSCs exert their function through direct inhibition of CD4 T cell proliferation in a cell-to-cell contact independent fashion. Mechanistically, we demonstrate that PDPN LNSCs mediate T cell growth arrest and induction of apoptosis to activated CD69CD4 T cells. Importantly, LTbR-Ig-mediated blockade of PDPN LNSCs expansion and function significantly attenuates melanoma tumor growth and enhances the infiltration and proliferation of CD4 TILs. Overall, our findings decipher a novel role of PDPN-expressing LNSCs in the elimination of CD4 TILs and propose a new target for tumor immunotherapy.
检查点阻断在肿瘤免疫治疗中的有益效果仅限于肿瘤浸润淋巴细胞(TIL)增加的患者。描绘协调TIL存在的调控网络对于设计有效的免疫疗法具有巨大潜力。表达血小板源性生长因子受体β/ gp38(PDPN)的淋巴结基质细胞(LNSC)存在于肿瘤基质中;然而,它们在调节TIL方面的作用仍不清楚。在此,我们证明将体外分离的PDPN LNSC瘤内注射到荷黑素瘤小鼠中会导致TIL消除并促进肿瘤生长。作为支持,PDPN LNSC以不依赖细胞间接触的方式通过直接抑制CD4 T细胞增殖发挥其功能。从机制上讲,我们证明PDPN LNSC介导T细胞生长停滞并诱导活化的CD69CD4 T细胞凋亡。重要的是,LTbR-Ig介导的对PDPN LNSC扩增和功能的阻断显著减弱黑素瘤肿瘤生长并增强CD4 TIL的浸润和增殖。总体而言,我们的研究结果揭示了表达PDPN的LNSC在消除CD4 TIL中的新作用,并提出了肿瘤免疫治疗的新靶点。